Cargando…

Use of smartphone application versus written titration charts for basal insulin titration in adults with type 2 diabetes and suboptimal glycaemic control (My Dose Coach): multicentre, open-label, parallel, randomised controlled trial

BACKGROUND: The majority of people with type 2 diabetes who require insulin therapy use only basal insulin in combination with other anti-diabetic agents. We tested whether using a smartphone application to titrate insulin could improve glycaemic control in people with type 2 diabetes who use basal...

Descripción completa

Detalles Bibliográficos
Autores principales: Hermanns, Norbert, Ehrmann, Dominic, Finke-Groene, Katharina, Krichbaum, Michael, Roos, Timm, Haak, Thomas, Freckmann, Guido, Kulzer, Bernhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636267/
https://www.ncbi.nlm.nih.gov/pubmed/37954005
http://dx.doi.org/10.1016/j.lanepe.2023.100702
_version_ 1785133175336337408
author Hermanns, Norbert
Ehrmann, Dominic
Finke-Groene, Katharina
Krichbaum, Michael
Roos, Timm
Haak, Thomas
Freckmann, Guido
Kulzer, Bernhard
author_facet Hermanns, Norbert
Ehrmann, Dominic
Finke-Groene, Katharina
Krichbaum, Michael
Roos, Timm
Haak, Thomas
Freckmann, Guido
Kulzer, Bernhard
author_sort Hermanns, Norbert
collection PubMed
description BACKGROUND: The majority of people with type 2 diabetes who require insulin therapy use only basal insulin in combination with other anti-diabetic agents. We tested whether using a smartphone application to titrate insulin could improve glycaemic control in people with type 2 diabetes who use basal insulin. METHODS: This was a 12-week, multicentre, open-label, parallel, randomised controlled trial conducted in 36 diabetes practices in Germany. Eligible participants had type 2 diabetes, a BMI ≥25.0 kg/m(2), were on basal insulin therapy or were initiating basal insulin therapy, and had suboptimal glycaemic control (HbA1c >7.5%; 58.5 mmol/mol). Block randomisation with 1:1 allocation was performed centrally. Participants in the intervention group titrated their basal insulin dose using a smartphone application (My Dose Coach) for 12 weeks. Control group participants titrated their basal insulin dose according to a written titration chart. The primary outcome was the baseline-adjusted change in HbA1c at 12 weeks. The intention-to-treat analysis included all randomised participants. RESULTS: Between 13 July 2021 and 21 March 2022, 251 study participants were randomly assigned (control group: n = 123; intervention group: n = 128), and 236 completed the follow-up phase (control group: n = 119; intervention group: n = 117). Regarding the HbA1c a model-based adjusted between-group difference of −0.31% (95% CI: 0.01%–0.69%; p = 0.0388) in favour of the intervention group was observed. There were 30 adverse events reported: 16 in the control group, 14 in the intervention group. Of these, 15 adverse events were serious. No event was considered to be related to the investigational device. INTERPRETATION: Study results suggest that utilizing this digital health smartphone application for basal insulin titration may have resulted in a comparatively greater reduction in HbA1c levels among individuals with type 2 diabetes, as compared to basal insulin titration guided by a written titration schedule. No negative effect on safety outcomes was observed. FUNDING: 10.13039/100019944Sanofi-Aventis Deutschland GmbH.
format Online
Article
Text
id pubmed-10636267
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-106362672023-11-11 Use of smartphone application versus written titration charts for basal insulin titration in adults with type 2 diabetes and suboptimal glycaemic control (My Dose Coach): multicentre, open-label, parallel, randomised controlled trial Hermanns, Norbert Ehrmann, Dominic Finke-Groene, Katharina Krichbaum, Michael Roos, Timm Haak, Thomas Freckmann, Guido Kulzer, Bernhard Lancet Reg Health Eur Articles BACKGROUND: The majority of people with type 2 diabetes who require insulin therapy use only basal insulin in combination with other anti-diabetic agents. We tested whether using a smartphone application to titrate insulin could improve glycaemic control in people with type 2 diabetes who use basal insulin. METHODS: This was a 12-week, multicentre, open-label, parallel, randomised controlled trial conducted in 36 diabetes practices in Germany. Eligible participants had type 2 diabetes, a BMI ≥25.0 kg/m(2), were on basal insulin therapy or were initiating basal insulin therapy, and had suboptimal glycaemic control (HbA1c >7.5%; 58.5 mmol/mol). Block randomisation with 1:1 allocation was performed centrally. Participants in the intervention group titrated their basal insulin dose using a smartphone application (My Dose Coach) for 12 weeks. Control group participants titrated their basal insulin dose according to a written titration chart. The primary outcome was the baseline-adjusted change in HbA1c at 12 weeks. The intention-to-treat analysis included all randomised participants. RESULTS: Between 13 July 2021 and 21 March 2022, 251 study participants were randomly assigned (control group: n = 123; intervention group: n = 128), and 236 completed the follow-up phase (control group: n = 119; intervention group: n = 117). Regarding the HbA1c a model-based adjusted between-group difference of −0.31% (95% CI: 0.01%–0.69%; p = 0.0388) in favour of the intervention group was observed. There were 30 adverse events reported: 16 in the control group, 14 in the intervention group. Of these, 15 adverse events were serious. No event was considered to be related to the investigational device. INTERPRETATION: Study results suggest that utilizing this digital health smartphone application for basal insulin titration may have resulted in a comparatively greater reduction in HbA1c levels among individuals with type 2 diabetes, as compared to basal insulin titration guided by a written titration schedule. No negative effect on safety outcomes was observed. FUNDING: 10.13039/100019944Sanofi-Aventis Deutschland GmbH. Elsevier 2023-07-24 /pmc/articles/PMC10636267/ /pubmed/37954005 http://dx.doi.org/10.1016/j.lanepe.2023.100702 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles
Hermanns, Norbert
Ehrmann, Dominic
Finke-Groene, Katharina
Krichbaum, Michael
Roos, Timm
Haak, Thomas
Freckmann, Guido
Kulzer, Bernhard
Use of smartphone application versus written titration charts for basal insulin titration in adults with type 2 diabetes and suboptimal glycaemic control (My Dose Coach): multicentre, open-label, parallel, randomised controlled trial
title Use of smartphone application versus written titration charts for basal insulin titration in adults with type 2 diabetes and suboptimal glycaemic control (My Dose Coach): multicentre, open-label, parallel, randomised controlled trial
title_full Use of smartphone application versus written titration charts for basal insulin titration in adults with type 2 diabetes and suboptimal glycaemic control (My Dose Coach): multicentre, open-label, parallel, randomised controlled trial
title_fullStr Use of smartphone application versus written titration charts for basal insulin titration in adults with type 2 diabetes and suboptimal glycaemic control (My Dose Coach): multicentre, open-label, parallel, randomised controlled trial
title_full_unstemmed Use of smartphone application versus written titration charts for basal insulin titration in adults with type 2 diabetes and suboptimal glycaemic control (My Dose Coach): multicentre, open-label, parallel, randomised controlled trial
title_short Use of smartphone application versus written titration charts for basal insulin titration in adults with type 2 diabetes and suboptimal glycaemic control (My Dose Coach): multicentre, open-label, parallel, randomised controlled trial
title_sort use of smartphone application versus written titration charts for basal insulin titration in adults with type 2 diabetes and suboptimal glycaemic control (my dose coach): multicentre, open-label, parallel, randomised controlled trial
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636267/
https://www.ncbi.nlm.nih.gov/pubmed/37954005
http://dx.doi.org/10.1016/j.lanepe.2023.100702
work_keys_str_mv AT hermannsnorbert useofsmartphoneapplicationversuswrittentitrationchartsforbasalinsulintitrationinadultswithtype2diabetesandsuboptimalglycaemiccontrolmydosecoachmulticentreopenlabelparallelrandomisedcontrolledtrial
AT ehrmanndominic useofsmartphoneapplicationversuswrittentitrationchartsforbasalinsulintitrationinadultswithtype2diabetesandsuboptimalglycaemiccontrolmydosecoachmulticentreopenlabelparallelrandomisedcontrolledtrial
AT finkegroenekatharina useofsmartphoneapplicationversuswrittentitrationchartsforbasalinsulintitrationinadultswithtype2diabetesandsuboptimalglycaemiccontrolmydosecoachmulticentreopenlabelparallelrandomisedcontrolledtrial
AT krichbaummichael useofsmartphoneapplicationversuswrittentitrationchartsforbasalinsulintitrationinadultswithtype2diabetesandsuboptimalglycaemiccontrolmydosecoachmulticentreopenlabelparallelrandomisedcontrolledtrial
AT roostimm useofsmartphoneapplicationversuswrittentitrationchartsforbasalinsulintitrationinadultswithtype2diabetesandsuboptimalglycaemiccontrolmydosecoachmulticentreopenlabelparallelrandomisedcontrolledtrial
AT haakthomas useofsmartphoneapplicationversuswrittentitrationchartsforbasalinsulintitrationinadultswithtype2diabetesandsuboptimalglycaemiccontrolmydosecoachmulticentreopenlabelparallelrandomisedcontrolledtrial
AT freckmannguido useofsmartphoneapplicationversuswrittentitrationchartsforbasalinsulintitrationinadultswithtype2diabetesandsuboptimalglycaemiccontrolmydosecoachmulticentreopenlabelparallelrandomisedcontrolledtrial
AT kulzerbernhard useofsmartphoneapplicationversuswrittentitrationchartsforbasalinsulintitrationinadultswithtype2diabetesandsuboptimalglycaemiccontrolmydosecoachmulticentreopenlabelparallelrandomisedcontrolledtrial